Observational analysis explores myelodysplastic syndrome with del(5q), suggesting varied outcomes and treatment options.
The only cytogenetic alteration defining a subtype of a myelodysplastic syndrome is represented by the deletion of the long arm of chromosome 5 (del(5q)), now classified as MDS with isolated del(5q). This subtype is associated with a peculiar phenotype mainly dependent by the haploinsufficiency of several genes located on the deleted arm of chromosome 5. These patients show a good prognosis and respond to treatment with lenalidomide, but some cases progress to acute myeloid leukemia. Molecular studies have in part elucidated th heterogeneity of MDS with isolated del(5q) mainly related to the association with different co-mutations that may affect leukemic transformation and survival.
No takes yet. Share an insight, caveat, or question.
Testa et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: